Ayala Pharmaceuticals (ADXS) News Today → This military-backed stock “owns” AI market (From Porter & Company) (Ad) Free ADXS Stock Alerts $0.22 -0.01 (-2.27%) (As of 04:30 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18, 2024 | americanbankingnews.comAyala Pharmaceuticals (NASDAQ:ADXS) Now Covered by Analysts at StockNews.comMay 9, 2024 | globenewswire.comAyala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting ObligationsApril 2, 2024 | seekingalpha.comImmunome: An Oncology Powerhouse In The MakingMarch 26, 2024 | globenewswire.comAyala Pharmaceuticals Announces Completion of Sale of AL102 to ImmunomeMarch 16, 2024 | finance.yahoo.comIMNM Oct 2024 22.500 callMarch 16, 2024 | finance.yahoo.comIMNM Oct 2024 25.000 callMarch 16, 2024 | finance.yahoo.comIMNM Oct 2024 25.000 putMarch 16, 2024 | finance.yahoo.comIMNM Oct 2024 45.000 callFebruary 20, 2024 | businesswire.comImmunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid TumorsFebruary 10, 2024 | msn.comAdvaxis Executes Strategic Unregistered Equity SalesFebruary 7, 2024 | msn.comAdvaxis Announces Definitive Agreement with Ayala PharmaceuticalsFebruary 6, 2024 | msn.comImmunome to buy AL102, a phase 3 asset for treatment of desmoid tumorsFebruary 6, 2024 | finance.yahoo.comImmunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala PharmaceuticalsNovember 24, 2023 | morningstar.comAyala Pharmaceuticals Inc Ordinary Shares ADXSNovember 20, 2023 | sfgate.comAyala Pharmaceuticals: Fiscal Q4 Earnings SnapshotNovember 17, 2023 | msn.comLadenburg Thalmann Downgrades Ayala Pharmaceuticals (ADXS)October 23, 2023 | finance.yahoo.comAyala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023October 19, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces Closing of Merger with BiosightAugust 10, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 3, 2023 | investing.comAyala Pharmaceuticals Inc (ADXS)August 1, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023July 27, 2023 | finance.yahoo.comAyala Pharmaceuticals and Biosight Enter into Definitive Merger AgreementJuly 5, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid TumorsJune 5, 2023 | finance.yahoo.comUpdated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual MeetingMay 25, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual MeetingMay 23, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate UpdateMay 20, 2023 | health.usnews.comArmando AyalaApril 27, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingApril 13, 2023 | uk.finance.yahoo.comAyala Pharmaceuticals, Inc. (ADXS)April 12, 2023 | forbes.comHubei Biocause PharmaceuticalMarch 3, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring CommitteeFebruary 10, 2023 | finance.yahoo.comAyala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022January 19, 2023 | finance.yahoo.comAdvaxis and Ayala Pharmaceuticals Complete MergerDecember 25, 2022 | finance.yahoo.comAdvaxis, Inc. (ADXS) Stock Historical Prices & Data - Yahoo FinanceOctober 20, 2022 | streetinsider.comForm 8-K Advaxis, Inc. For: Oct 18 - StreetInsider.comOctober 20, 2022 | finance.yahoo.comRedHill Biopharma Shares Surge New Treatment Patent For Its Late-Stage COVID-19 Candidate - Yahoo FinanceOctober 19, 2022 | marketscreener.comADVAXIS, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure (form 8-K) - Marketscreener.comOctober 19, 2022 | benzinga.comWhy United Airlines Shares Are Trading Higher? Here Are 43 Stocks Moving In Wednesday’s Mid-Day Session - - BenzingaOctober 19, 2022 | businesswire.comAYLA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Ayala Pharmaceuticals, Inc. Is Fair to Shareholders - Business WireOctober 19, 2022 | baystreet.caAyala, Advaxis Merge - Baystreet.caOctober 19, 2022 | marketwatch.comAyala Pharmaceuticals, Advaxis to Combine in Stock Deal >AYLA ADXS - MarketWatchOctober 19, 2022 | finance.yahoo.comAyala Pharmaceuticals and Advaxis Enter into Merger Agreement - Yahoo FinanceOctober 19, 2022 | seekingalpha.comAyala stock rises 16% on all-stock merger with Advaxis to focus on cancer drugs - Seeking AlphaOctober 19, 2022 | globenewswire.comAdvaxis and Ayala Pharmaceuticals Enter into Merger Agreement - GlobeNewswireOctober 17, 2022 | globenewswire.comRich Insights into the Metastatic Urothelial Carcinoma Clinical Trial Analysis Featuring 40+ Companies and Therapies | DelveInsight - GlobeNewswireOctober 13, 2022 | globenewswire.comHerbal Medicinal Products Market Is Expected to Grasp the Value of USD 177.65 Billion with Growing CAGR of 6.83% by 2029, Size, Shares, Trends, Growth and Revenue Outlook - GlobeNewswireOctober 4, 2022 | finance.yahoo.comBlueSphere Bio Appoints Keir Loiacono as Chief Executive Officer - Yahoo FinanceOctober 4, 2022 | benzinga.comBlueSphere Bio Appoints Keir Loiacono as Chief Executive Officer - BenzingaSeptember 28, 2022 | streetinsider.comReunion Neuroscience (REUN) Appoints Greg Mayes as President and CEO - StreetInsider.comSeptember 28, 2022 | finance.yahoo.comReunion Neuroscience Inc. Appoints Greg Mayes as President and Chief Executive Officer Get Ayala Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter. Email Address What is Nvidia’s New $1 Trillion Superproject? (Ad)Nvidia recently added $277 billion in market cap … IN ONE DAY. Find out details on these three critical Nvidia partners immediately. ADXS Media Mentions By Week ADXS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADXS News Sentiment▼0.000.44▲Average Medical News Sentiment ADXS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADXS Articles This Week▼10▲ADXS Articles Average Week Get Ayala Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CNS Pharmaceuticals News PaxMedica News Galmed Pharmaceuticals News Qualigen Therapeutics News Avenue Therapeutics News Clearmind Medicine News Salarius Pharmaceuticals News Dermata Therapeutics News CohBar News Sonoma Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ADXS) was last updated on 5/23/2024 by MarketBeat.com Staff From Our Partners[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersWrite this ticker symbol down…StocksToTrade**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge AlertsNew Options need New Trading StrategiesNetpicksThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsBuy this small stock before coming AI Tidal WaveChaikin AnalyticsUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ayala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
